Retatrutide · GLP3 RT
A modified 39-residue peptide with a lipid-linked lysine.
Structure & history · Laboratory research reference

Quick facts
- Compound class
- Synthetic lipidated peptide
- Sequence length
- 39 amino acids
- Molecular formula
- C221H342N46O68
- Average molar mass
- 4,731 g/mol
- Origins & first reports
- Developed by Eli Lilly; discovery characterization published in 2022 as LY3437943.
Molecular entity excludes counterions and water. GLP3 RT is a catalogue label, not a separate standardized identity.
Did you know?
- Its sequence contains noncanonical amino-acid residues.
- Lys17 carries a linker-connected C20 fatty-diacid substituent.
- The C-terminal residue is serinamide.
Published research
- 2023Clinical
The New England Journal of Medicine
Phase 2 randomised trial design; described by design and topic only.
View on PubMed - 2023Clinical
The Lancet
Randomised, double-blind, placebo- and active-controlled phase 2 design; described by design and topic only.
View on PubMed - 2024Clinical
Nature Medicine
Randomised phase 2a design examining liver fat measures; described by design and topic only.
View on PubMed
Summaries describe published research for reference only. Peptiora materials are supplied for in-vitro laboratory research and are not intended for human or veterinary use.

Research timeline
2022
USAN Council adopted the name retatrutide.
2022
LY3437943 molecular characterization published.
2024
Receptor-bound structural analysis published.
Source notes
Research materials & tools
Related peptides & research materials
Metabolic Signalling · 4 min read
AOD-9604
A fragment analogue whose structure includes a disulfide bridge. Synthetic disulfide-bridged peptide analogue.
Read articleAll products supplied by Peptiora are for laboratory research use only (RUO). Not for human or veterinary use, diagnostic use, or therapeutic use.
